Business Wire

ABB

19.11.2020 06:48:08 CET | Business Wire | Press release

Share
ABB Capital Markets Day 2020

ABB will be hosting its Capital Markets Day today, November 19, starting 11.30 am CET, at which CEO, Björn Rosengren, and CFO, Timo Ihamuotila, as well as the four business area Presidents, will give an update on the recent strategic and operational developments, including:

  • Improving performance under ABB Way
  • Review of business portfolio
  • ABB’s digital strategy
  • Updated financial framework and long-term sustainability targets

“ABB is a leading technology company, now and in the future. We have the global R&D capabilities, digital solutions and innovation focus to support our customers. The COVID-19 pandemic still weighs on the near-term outlook, but the long-term market trends of electrification, automation, digitalization and energy efficiency remain intact. At the same time, we are taking additional steps to improve performance in order to drive value creation for all stakeholders going forward,” said CEO Björn Rosengren.

Improved performance in the making

Since the start of this year, ABB has further decentralized its organization to bring operating decisions closer to the customer and successfully rolled out its new operating model called ABB Way, including the introduction of a scorecard-based performance management system reinforced through incentivization. This creates a clear focus on stability and profitability before growth in order to strengthen underperforming divisions.

Furthermore, ABB has carried out a portfolio review of its divisions to ascertain whether it is ultimately the best owner. As a result, ABB has decided to explore all options to exit three divisions:

  • Turbocharging (Industrial Automation)
  • Mechanical Power Transmission (Motion)
  • Power Conversion (Electrification)

These divisions represent roughly $1.75 billion of combined annual revenues or approximately six percent of ABB’s total revenues.

“All three divisions are high-quality businesses, with Operational EBITA margins above the group’s target margin corridor. In this process, we will seek the best value-accretive solution for ABB and those businesses and not put ourselves under time pressure,” said Rosengren. “Furthermore, portfolio reviews will continue to be a key element of the ABB Way.”

ABB will increase the number of divisions to 20 as of January 1, 2021, due to a split in the Motion business area portfolio, while Industrial Automation will be renamed Process Automation to better reflect its customer base.

CFO Timo Ihamuotila will highlight in his presentation that ABB has delivered on sustainable cost reductions: “Due to the reorganization of the Group, the ABB-OS target of $500 million net savings has been reached one year ahead of plan.”

ABB’s digital strategy

ABB has recently carried out a review of its digital strategy under the ABB Ability™ brand, which is comprised of software-enabled products and systems, as well as software and digital services. The company intends to accelerate the expansion of its digital offering that is tailored to specific sectors or applications based on ABB’s domain expertise. This will be done through increasing R&D and investments to about 5 percent of revenues per year and will be led by the business. This approach creates superior value for customers and drives a higher quality of revenues for the company. ABB will also continue to pursue select strategic partnerships in the digital sphere, as well as synergetic bolt-on acquisitions.

Updated financial framework

ABB is retaining its financial framework with modifications to certain targets in order to align with the ABB Way.

 

 

Guidance

 

Medium term ambitions

Revenue growth

 

3-5% annual average through economic cycle1

 

~2/3 comparable, ~1/3 inorganic

Operational EBITA margin corridor

 

Group 13-16%

 

Upper half of range as from 2023

 

 

Electrification 15-19%

Industrial Automation 12-16%

Motion 15-19% (previously 14-18%)

Robotics & Discrete Automation 13-17%

 

 

ROCE

 

15-20%

 

Steady improvement

FCF conversion to net income

 

~100%

 

Maintain solid track record

Basic EPS growth

 

EPS growth > revenue growth

 

Effective tax rate ~25% as from 2023
EPS rising strongly due to capital structure optimization program

ABB’s capital allocation priorities remain unchanged, including funding organic growth, a rising sustainable dividend per share and value-creating acquisitions. As previously announced, ABB intends to return to shareholders net cash proceeds from the Power Grids divestment of $7.6-7.8 billion.

“ABB aims to deliver attractive returns to shareholders and retain a ‘single A’ credit rating,” said CFO Timo Ihamuotila. “We also aim to complete most of our capital structure optimization program by the end of the year in order to further de-risk our balance sheet and further improve performance.”

Long-term sustainability targets

ABB is announcing the launch of its new sustainability strategy and targets for 2030, which is rooted in ABB’s Purpose and centered on an intensive stakeholder listening phase comprised of interviews and analyzed feedback. Based on this, the company has created a comprehensive sustainability strategy that combines ABB’s higher ambition, impact, measurability and accountability across its value chain of operations, customers, suppliers and society at large.

We enable a low carbon society

 

We preserve resources

 

We promote social progress

Carbon neutrality in own operations

 

80% of ABB products and solutions covered by circularity approach

 

Zero harm to our people and contractors

Support our customers in reducing annual CO2 emissions by >100 Mt2

 

Zero waste to landfill3

 

Comprehensive D&I framework4 ; 25% women among ABB leaders

Supply chain emissions reduction

 

Supplier sustainability framework

 

Top-tier employee engagement score in our industry

 

 

 

 

Impactful support for community-building initiatives

Integrity and transparency across our value chain

Further details available at go.abb/sustainability

“ABB is embedding sustainability in everything we do in order to create long-term value. Foremost, we are enabling customers to reduce their emissions and preserve resources because this is where ABB’s technology can have the greatest impact. Furthermore, our new targets will be tied to employee incentive plans thus driving performance and culture within our group, while we are proud to be contributing to the United Nations’ Sustainable Development Goals,” said Rosengren.

Note to editors : The Capital Markets Day, CEO/CFO presentation, as well as presentations from Business Areas and Divisions, can be followed under: https://global.abb/group/en/investors/strategy-events/capital-markets-day-2020 from 11.30 am to 5.15 pm CET.

ABB (ABBN: SIX Swiss Ex) is a leading global technology company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by about 110,000 talented employees in over 100 countries. www.abb.com

Important notice about forward-looking information

This press release includes forward-looking information and statements which are based on current expectations, estimates and projections about the factors that may affect our future performance, including the economic conditions of the regions and industries that are major markets for ABB. These expectations, estimates and projections are generally identifiable by statements containing words such as “anticipates”, “expects,” “believes,” “estimates,” “plans”, “targets”, “aims” or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release and which could affect our ability to achieve any or all of our stated targets. The important factors that could cause such differences include, among others, business risks associated with the COVID-19 pandemic, the volatile global economic environment and political conditions, costs associated with compliance activities, market acceptance of new products and services, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

_____________________
1
Calculated to exclude FX impacts and transformational acquisitions and divestments, includes bolt-on acquisitions and divestments within divisions.
2 Annual savings in the year 2030 from all solutions provided to customers 2021-30
3 Wherever local conditions allow
4 Diversity & Inclusion framework

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye